Sangeeta K. Cheema, Ph.D.

Sangeeta focuses her practice on patent procurement and licensing of life science matters, in addition to strategic counseling for the same. She received a Ph.D. in Cancer Biology from University of Texas MD Anderson Cancer Center, in 2002. She received an M.S. (1992) and a B.S.(1990) in Microbiology from Panjab University, in Chandigarh, India. Sangeeta received her J.D. (cum laude) from South Texas College of Law in 2011.

Sangeeta has extensive experience in drafting and prosecuting patent applications related to biotechnological and life science areas with specialization in cancerbiology, molecular biology, physiology, neurology, biochemistry, cell and molecular biology, microbiology, medical devices and nanotechnology.

Prior to joining Seed IP, Sangeeta served as IP counsel for the University of Houston, where she advised, counseled, and assisted on matters related to IP and licensing transactions for the Office of Technology Transfer and Innovation. Prior to this, she served as the Head of Patent Group at Unilever in India. Here she performed a global function as part of global legal team to support intellectual property (IP) needs of Unilever in the Fast Moving Consumer Goods (FMCG) Sector for inventions arising at Research and Development (R&D) site in India.

Sangeeta also previously served as a patent agent and staff attorney at Winstead PC, in Houston, Texas, where she managed and assisted with prosecution of U.S. and foreign patent applications, including drafting and preparation of U.S. and international patent applications, responses to Office Actions, and conducted phone interview with the Examiners, and worked closely with foreign associates on matters related to foreign patent prosecution.

South Texas College of Law

J.D. (cum laude) 2011

 

University of Texas MD Anderson Cancer Center

Cancer Biology

Ph.D. 2002

 

Panjab University

Microbiology

M.S. 1992

 

Panjab University

Microbiology

B.S. 1990

Sangeeta is admitted to the Texas State Bar, and is registered to practice before the United States Patent and Trademark Office. She is a member of the Washington State Patent Law Association (WSPLA) and Life Science Washington.

Videos

Co-author of the WinTech blog, which provides legal insight for start-ups and established technology businesses.

Sangeeta K. Cheema and Frank Amini, “Recent Developments in Patent Law”. Presented to the Office of Technology Transfer of the University of Texas Medical Branch at Galveston, June 18, 2014.

Sangeeta K. Cheema and Frank Amini, “Using the Patent System to Protect your Biomedical Inventions in the U.S. and Abroad”. Presented to Biomedical and Technology Club of Houston, April 1, 2014.

Sangeeta K. Cheema, Ellen Chen, Lonnie D. Shea and Anshu B. Mathur, Regulation and Guidance of Cell Behavior For Tissue Regeneration via siRNA Mechanism, 16 Wound Repair and Regeneration 286-95 (2007).

Sangeeta K. Cheema, Andrea S. Gobin, Robyn Rhea, Gabriel Lopez-Berestein, Robert A. Newman and Anshu B. Mathur, Silk Fibroin Mediated Delivery of Liposomal Emodin To Breast Cancer Cells, 341 International Journal of Pharmaceutics 221-29 (2007).

Chen E., Cheema S.K., and Mathur A.B., Potential uses of RNA interference in tissue engineering: a silencing mechanism that speaks volumes, Poster Presentation, Rice University Center for Biomedical Engineering, Houston, TX 2005.

Sangeeta K. Cheema and Anshu B. Mathur, Promotion of Stable Vasculature via siRNA Technology, “Podium Presentation”, 2005 8th Annual Tissue Engineering Society International (TESI) Meeting, Shanghai, China; and 2006 Houston Society of Engineering and Biomedical Sciences (HSEBS) Annual Meeting, Houston, TX.

Cheema S.K., Gobin A.S., Rhea R., Newman R.A., Mathur A.B., Silk Fibroin Mediated Delivery of Liposomal Emodin to Breast Cancer Cells, Poster Presentation at the 2005Biomedical Engineering Society Annual Fall Meeting, Baltimore, MD.

Angela M. Sanguino, Arturo Chavez, Sangeeta Cheema, Ana Tari and Gabriel Lopez-Berestein, Androgen receptor controls the expression of WT1 in the androgen dependent prostate cancer cell line LNCAP, 46 Proc. Amer. Assoc. Cancer Res. 1029 (2005).

Cheema, S. K., Misra, S., Rangnekar, V.M., Tari,A.M., Kumar, R., and Lopez-Berestein, G., Par-4 Transcriptionally Regulates Bcl-2through a WT1-binding Site on the bcl-2 Promoter , 278 J. Biol. Chem.19995 – 20005 (2003).

Sangeeta K. Cheema, PAR-4 Mediates Regulation ofBcl-2 via a WT1 binding site on the bcl-2 promoter in Advanced Prostate Carcinoma, Invited Speaker at the 2003 Bioimmunotherapy Faculty Retreat held at the Houstonian, Houston, TX.

Cheema, S. K., Misra, S., Rangnekar, V.M., Tari, A.M., Kumar, R., and Lopez-Berestein, G., PAR-4 Mediates Regulation of Bcl-2via a WT1 binding site on the bcl-2 promoter in Advanced Prostate Carcinoma, Poster at the 2003 7th Annual Trainee Recognition Day and Research Exposition at the University of Texas MD Anderson Cancer Center, Houston, TX.

Cheema, S. K., Rangnekar, V.M., Tari, A.M. and Lopez-Berestein, G., Par-4 transcriptionally regulates Bcl-2 in Prostate Cancer Cells,42 Proc. Amer. Assoc. Cancer Res. 591(2002).

Cheema, S. K., Rangnekar, V.M., Tari, A.M. and Lopez-Berestein, G., Growth Regulation of Prostate Cancer Cell Lines byBcl-2 Down-modulation, 41 Proc. Amer. Assoc. Cancer Res. 264 (2001).

Mehta, K. and Cheema, S. K., Retinoid-mediated Signaling Pathways in CD38Antigen Expressing Myeloid Leukemia Cells, 32 Leukemia & Lymphoma 441-49 (1999).

Invited Keynote speaker at the M.D. Anderson Cancer Center, Experimental Therapeutics Academic Program Research Retreat, 2015.

Honors & Awards